<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

2 min read

COVID-19 Headwinds: Q321 OrthoBio Market Recap

12/29/21 11:49 AM

OrthoBio Market Recap Header V2Renewed COVID-19 headwinds mute overall Q3 results, however, the soft tissue repair segment remains resilient

Impact of the Delta variant was felt broadly across OrthoBio, with virtually all publicly traded companies observing a reduction in surgical volume (relative to forecast) directly attributable to a resurgence of COVID-19. Overall, OrthoBio revenue declined, primarily driven by a sharp reduction in Bone Replacement revenue. Several companies noted the decrease in surgical volumes was most acute in August and September due to shortages in hospital staffing. Weakness was most closely tied to deferrable, elective, complex spine procedures.

Among the many topics covered in detail in our comprehensive Q321 OrthoBio Market Recap* are:

  • Complete Q321 OrthoBio Market Overview
  • SmartTRAK's Expert Analysis and Insights
  • All Market News including Revenues, Data, Charts and Shares
  • Notable Commentary
  • New Product Introductions
  • Regulatory Approvals
  • M&A/Deals/Financing

Smith & Nephew* (SNN) and the Soft Tissue Replacement segment was the lone bright spot in Q3 (up +20.2%), driven by continued market acceptance and adoption of SNN’s REGENETEN product. SNN was bullish on its ...

Read the entire Q321 OrthoBio Market Recap and expert analysis, including news, data, charts, company revenues and shares*

*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

Learn More

SmartTRAK has launched five new modules in 2021. Click here to see details of all the exciting new content now available on SmartTRAK.


Topics: Orthobiologics

James Petricek
Written by James Petricek

20+ years operational and management consulting experience in orthobiologics and regenerative medicine with roles in product development, marketing and business development. Prior management positions with BioMimetic Therapeutics and Synthes.

    Follow Us on Social Media

    Recent Articles